New Vaccine Platforms (NVP) Program

The Administration for Strategic Preparedness and Response (ASPR) issued this special notice for the New Vaccine Platforms (NVP) Program to identify and advance innovative vaccine technologies for the Biomedical Advanced Research and Development Authority (BARDA) medical countermeasure portfolio. The program seeks platform technologies, such as protein, viral vector, or bacterial vector-based approaches, that have already demonstrated the ability to manufacture Phase 1 clinical trial material. These platforms must be safe, effective across multiple pathogen families, and capable of efficient development and manufacturing. Eligible offerors may include single organizations with full technology solutions or two-part teams providing both antigen expression and vaccine carrier or formulation capabilities.

The primary objective is to conduct a staged capability demonstration across at least two emerging infectious disease threats, which may include Lassa virus, Nipah virus, chikungunya virus, or West Nile virus. The demonstration process involves three stages: manufacturing demonstration from start to Phase 1 material, nonclinical activities to support an Investigational New Drug application, and a Phase 1 clinical trial. Future demonstrations may expand to include pandemic influenza or other threats aligned with the BARDA chemical, biological, radiological, and nuclear mission. This initiative supports national health security by ensuring the medical countermeasure portfolio can respond effectively to public health incidents through streamlined vaccine development.

The place of performance is Washington, DC, and the primary point of contact is Contracting Officer Erin Greninger. This notice includes two attachments detailing Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) priority biological threats and the Rapid Response Partnership Vehicle. Published on March 26, 2026, the notice is categorized under the Administration for Strategic Preparedness and Response. No specific NAICS code, PSC code, or set-aside designations were identified in the metadata.